|
1
|
Seyedian SS, Nokhostin F and Malamir MD: A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 12:113–122. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, et al: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 68 (Suppl 3):s1–s106. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, Lee KH and Shin JI: Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev. 18:439–454. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Singh S, Fumery M, Sandborn WJ and Murad MH: Systematic review with network meta-analysis: First-and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 47:162–175. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wyant T, Fedyk E and Abhyankar B: An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 10:1437–1444. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343(d5928)2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen B and Benedetti A: Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev. 6(243)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Duval S and Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis,'. Biometrics. 56:455–463. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, et al: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 352:2499–2507. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I and Feagan BG: Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 18:1470–1479. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 369:699–710. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A and Smyth M: Efficacy of Vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 15:229–239.e5. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, et al: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 14(e0212989)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, et al: Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 158:562–572.e12. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Cohen A, Bitton A, Baker J, Dubé R, et al: Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 6:1370–1377. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, et al: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 369:711–721. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, et al: Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 147:618–627.e3. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B and Lasch K: Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 23:97–106. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, et al: Effects of vedolizumab in Japanese patients with Crohn's disease: A prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. J Gastroenterol. 55:291–306. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, et al: Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: Results from the VISIBLE 2 Randomised trial. J Crohns Colitis. 16:27–38. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Szigethy E, McLafferty L and Goyal A: Inflammatory bowel disease. Child Adolesc Psychiatr Clin N Am. 19:301–318. ix. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wallace KL, Zheng LB, Kanazawa Y and Shih DQ: Immunopathology of inflammatory bowel disease. World J Gastroenterol. 20:6–21. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Manichanh C, Borruel N, Casellas F and Guarner F: The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 9:599–608. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Latella G and Papi C: Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 18:3790–3799. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xu XR, Liu CQ, Feng BS and Liu ZJ: Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 20:3255–3264. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rosen MJ, Dhawan A and Saeed SA: Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 169:1053–1060. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 390:2769–2778. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG and Long MD: ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol. 114:384–413. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hering NA and Schulzke JD: Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig Dis. 27:450–454. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Strik AS, Bots SJ, D'Haens G and Löwenberg M: Optimization of anti-TNF therapy in patients with inflammatory bowel disease. Expert Rev Clin Pharmacol. 9:429–439. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ben-Horin S and Chowers Y: Tailoring anti-TNF therapy in IBD: Drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 11:243–255. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ben-Horin S and Chowers Y: Review article: Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 33:987–995. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA and Sinha S: Anti-Integrins for the treatment of inflammatory bowel disease: Current evidence and perspectives. Clin Exp Gastroenterol. 14:333–342. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hemler ME, Huang C, Takada Y, Schwarz L, Strominger JL and Clabby ML: Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem. 262:11478–11485. 1987.PubMed/NCBI
|
|
36
|
Lanzarotto F, Carpani M, Chaudhary R and Ghosh S: Novel treatment options for inflammatory bowel disease: Targeting alpha 4 integrin. Drugs. 66:1179–1189. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Soler D, Chapman T, Yang LL, Wyant T, Egan R and Fedyk ER: The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 330:864–875. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H and Peyrin-Biroulet L: French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis. 53:35–43. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW and Kaplan GG: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 142:46–54 e42. 2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ye Y, Manne S, Treem WR and Bennett D: Prevalence of inflammatory bowel disease in pediatric and adult populations: Recent estimates from large national databases in the United States,2007-2016. Inflamm Bowel Dis. 26:619–625. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang MC, Zhang LY, Han W, Shao Y, Chen M, Ni R, Wang GN, Wei FX, Zhang YW, Xu XD and Zhang YC: PRISMA-efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 93(e326)2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM and Loftus EV Jr: Systematic review with meta-analysis: Real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 53:1048–1064. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, Khanna R and Feagan BG: Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 21:1151–1159. 2015.PubMed/NCBI View Article : Google Scholar
|
